X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
index medicus (11) 11
female (10) 10
breast cancer (9) 9
middle aged (8) 8
cancer (7) 7
breast neoplasms - pathology (6) 6
breast neoplasms - surgery (6) 6
abridged index medicus (5) 5
adult (5) 5
breast neoplasms - drug therapy (5) 5
hematology, oncology and palliative medicine (5) 5
medicine, general & internal (5) 5
natural products (5) 5
oncology (5) 5
surgical adjuvant breast (5) 5
aged (4) 4
article (4) 4
chemotherapy (4) 4
clinical trials (4) 4
disease-free survival (4) 4
glycolipids (4) 4
internal medicine (4) 4
medical colleges (4) 4
tamoxifen (4) 4
treatment outcome (4) 4
women (4) 4
analysis (3) 3
biometry (3) 3
breast neoplasms - radiotherapy (3) 3
carcinoma (3) 3
chemistry, organic (3) 3
chemotherapy, adjuvant (3) 3
cyclophosphamide (3) 3
double-blind method (3) 3
health maintenance organizations (3) 3
history (3) 3
lumpectomy (3) 3
marine metabolites (3) 3
mastectomy, segmental (3) 3
patient outcomes (3) 3
postmenopause (3) 3
preoperative chemotherapy (3) 3
product development (3) 3
radiotherapy (3) 3
surgery (3) 3
survival (3) 3
trastuzumab (3) 3
united states (3) 3
womens health (3) 3
adjuvant treatment (2) 2
administration, oral (2) 2
age factors (2) 2
anthracyclines (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antineoplastic agents, hormonal - administration & dosage (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
aromatase inhibitors - administration & dosage (2) 2
aromatase inhibitors - therapeutic use (2) 2
axilla (2) 2
biopsy (2) 2
bowel project p-1 (2) 2
breast neoplasms - mortality (2) 2
canada (2) 2
cancer surgery (2) 2
cancer therapies (2) 2
carcinoma, ductal, breast - drug therapy (2) 2
carcinoma, ductal, breast - radiotherapy (2) 2
carcinoma, ductal, breast - surgery (2) 2
care and treatment (2) 2
combined modality therapy (2) 2
curtatone and montanara, battle of, italy, 1848 (2) 2
doxorubicin (2) 2
drug therapy (2) 2
follow-up (2) 2
kaplan-meier estimate (2) 2
lymphatic metastasis (2) 2
mastectomy (2) 2
neoadjuvant therapy (2) 2
neoplasm staging (2) 2
nitriles - administration & dosage (2) 2
nitriles - therapeutic use (2) 2
nmr spectroscopy (2) 2
postmenopausal women (2) 2
public health (2) 2
radiation therapy (2) 2
radiation-therapy (2) 2
randomized controlled trials as topic (2) 2
research (2) 2
risk factors (2) 2
structure elucidation (2) 2
studies (2) 2
tamoxifen - administration & dosage (2) 2
tamoxifen - therapeutic use (2) 2
terpenes and terpenoids (2) 2
therapy (2) 2
time factors (2) 2
triazoles - administration & dosage (2) 2
triazoles - therapeutic use (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 927 - 933
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 849 - 856
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated... 
Internal Medicine | INTRADUCTAL BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | RADIATION-THERAPY | B-17 | Breast Neoplasms - surgery | Triazoles - administration & dosage | Triazoles - adverse effects | Thrombosis - chemically induced | Age Factors | Humans | Middle Aged | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Mastectomy, Segmental | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Female | Embolism - chemically induced | Aromatase Inhibitors - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - surgery | Double-Blind Method | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Carcinoma, Ductal, Breast - radiotherapy | Tamoxifen - therapeutic use | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Lumpectomy | Medical colleges | Carcinoma | Radiation | Clinical trials | Postmenopausal women | Hormones | Tamoxifen | Radiotherapy | Biometry | Health maintenance organizations | Product development | Cancer | Chemotherapy | Womens health | Older people | Breast cancer | Radiation therapy | Cancer surgery
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 857 - 865
Journal Article